Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

783 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events.
Fox KA, Carruthers K, Steg PG, Avezum A, Granger CB, Montalescot G, Goodman SG, Gore JM, Quill AL, Eagle KA; GRACE Investigators. Fox KA, et al. Among authors: montalescot g. Eur Heart J. 2010 Mar;31(6):667-75. doi: 10.1093/eurheartj/ehp499. Epub 2009 Dec 8. Eur Heart J. 2010. PMID: 20007159 Free PMC article.
Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: findings from the global registry of acute coronary events (GRACE).
Montalescot G, Van de Werf F, Gulba DC, Avezum A, Brieger D, Kennelly BM, Mazurek T, Spencer F, White K, Gore JM; GRACE Investigators. Montalescot G, et al. Catheter Cardiovasc Interv. 2003 Nov;60(3):360-7. doi: 10.1002/ccd.10653. Catheter Cardiovasc Interv. 2003. PMID: 14571488
Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
Collet JP, Montalescot G, Agnelli G, Van de Werf F, Gurfinkel EP, López-Sendón J, Laufenberg CV, Klutman M, Gowda N, Gulba D; GRACE Investigators. Collet JP, et al. Among authors: montalescot g. Eur Heart J. 2005 Nov;26(21):2285-93. doi: 10.1093/eurheartj/ehi337. Epub 2005 Jun 2. Eur Heart J. 2005. PMID: 15932908 Clinical Trial.
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Booth J, Topol EJ; CHARISMA Investigators. Bhatt DL, et al. Among authors: montalescot g. Am Heart J. 2005 Sep;150(3):401. doi: 10.1016/j.ahj.2005.03.017. Am Heart J. 2005. PMID: 16169314 Clinical Trial.
Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes.
Mallat Z, Steg PG, Benessiano J, Tanguy ML, Fox KA, Collet JP, Dabbous OH, Henry P, Carruthers KF, Dauphin A, Arguelles CS, Masliah J, Hugel B, Montalescot G, Freyssinet JM, Asselain B, Tedgui A. Mallat Z, et al. Among authors: montalescot g. J Am Coll Cardiol. 2005 Oct 4;46(7):1249-57. doi: 10.1016/j.jacc.2005.06.056. J Am Coll Cardiol. 2005. PMID: 16198839 Free article.
783 results